These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Steidle C; Schwartz S; Jacoby K; Sebree T; Smith T; Bachand R; J Clin Endocrinol Metab; 2003 Jun; 88(6):2673-81. PubMed ID: 12788872 [TBL] [Abstract][Full Text] [Related]
43. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Swerdloff RS; Wang C Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501 [TBL] [Abstract][Full Text] [Related]
44. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Rolf C; Knie U; Lemmnitz G; Nieschlag E Clin Endocrinol (Oxf); 2002 May; 56(5):637-41. PubMed ID: 12030915 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. Brocks DR; Meikle AW; Boike SC; Mazer NA; Zariffa N; Audet PR; Jorkasky DK J Clin Pharmacol; 1996 Aug; 36(8):732-9. PubMed ID: 8877678 [TBL] [Abstract][Full Text] [Related]
46. A new testosterone gel (fortesta) for hypogonadism. Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933 [TBL] [Abstract][Full Text] [Related]
47. Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications. Swerdloff RS; Pak Y; Wang C; Liu PY; Bhasin S; Gill TM; Matsumoto AM; Pahor M; Surampudi P; Snyder PJ J Clin Endocrinol Metab; 2015 Sep; 100(9):3280-7. PubMed ID: 26120790 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. Javanbakht M; Singh AB; Mazer NA; Beall G; Sinha-Hikim I; Shen R; Bhasin S J Clin Endocrinol Metab; 2000 Jul; 85(7):2395-401. PubMed ID: 10902784 [TBL] [Abstract][Full Text] [Related]
49. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. Dinsmore WW; Wyllie MG BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877 [TBL] [Abstract][Full Text] [Related]
50. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982 [TBL] [Abstract][Full Text] [Related]
52. Transdermal testosterone delivery in castrated Yucatan minipigs: pharmacokinetics and metabolism. Xing QF; Lin S; Chien YW J Control Release; 1998 Mar; 52(1-2):89-98. PubMed ID: 9685939 [TBL] [Abstract][Full Text] [Related]
53. Contributors to the substantial variation in on-treatment testosterone levels in men receiving transdermal testosterone gels in randomized trials. Bhasin S; Travison TG; O'Brien L; MacKrell J; Krishnan V; Ouyang H; Pencina K; Basaria S Andrology; 2018 Jan; 6(1):151-157. PubMed ID: 28981994 [TBL] [Abstract][Full Text] [Related]
54. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. Raynaud JP; Gardette J; Rollet J; Legros JJ BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726 [TBL] [Abstract][Full Text] [Related]
55. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. Daniell HW; Lentz R; Mazer NA J Pain; 2006 Mar; 7(3):200-10. PubMed ID: 16516826 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men. Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757 [TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Braunstein GD; Sundwall DA; Katz M; Shifren JL; Buster JE; Simon JA; Bachman G; Aguirre OA; Lucas JD; Rodenberg C; Buch A; Watts NB Arch Intern Med; 2005 Jul; 165(14):1582-9. PubMed ID: 16043675 [TBL] [Abstract][Full Text] [Related]
58. Testosterone patches for female sexual dysfunction. Drug Ther Bull; 2009 Mar; 47(3):30-4. PubMed ID: 19261838 [TBL] [Abstract][Full Text] [Related]
59. Response to: Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Morgentaler A Int J Impot Res; 2008; 20(3):331; author reply 332. PubMed ID: 18475269 [No Abstract] [Full Text] [Related]
60. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. Dobs AS; Bachorik PS; Arver S; Meikle AW; Sanders SW; Caramelli KE; Mazer NA J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]